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Letter to the Editor: Proton Pump Inhibitors in Cirrhosis: A 
Marker of Morbid Conditions or a Cause of Mortality?
TO THE EDITOR:
We read with interest the study by Nardelli et al., 
which adds to a growing literature on the potential 
ills of proton pump inhibitors (PPIs) in patients 
with cirrhosis.(1) Their prospective design allowed for 
assessment of minimal hepatic encephalopathy (HE), 
and they reported that PPI use was independently 
associated with minimal HE, overt HE, and mortal-
ity. While we applaud the authors’ efforts, we are con-
cerned about residual confounding that may have led 
to misinterpretation of mortality results.
The authors outline that decreased gastric acid pro-
vides biological plausibility for the association between 
PPIs and Clostridium difficile colitis, spontaneous bac-
terial peritonitis, and pneumonia, which could explain 
some increased mortality in PPI users.(2) However, 
infections accounted for just over one third of deaths 
overall, type of infection was unreported, and cause of 
death stratified by PPI use was not included. PPI use 
was weakly associated with overt HE, but this is unlikely 
to account for the reported mortality, even when consid-
ered in combination with infections. This begs the ques-
tion of whether other explanations may exonerate PPIs.
It is possible that PPI use may merely be a marker of 
patient comorbidities. Increased health care use, smok-
ing, obesity, nonsteroidal anti-inflammatory drug use, 
and vascular disease are all potential confounders of 
PPI use and death.(3) These factors were not assessed. 
Furthermore, 42% of PPI users had “an appropriate” 
indication, which included recent gastrointestinal bleed 
and/or endoscopic ligation of varices, both of which 
may increase mortality independent of Model for End-
Stage Liver Disease or Child-Pugh score. It would 
therefore be worthwhile to examine the mortality 
among PPI users with strong versus weak indications.
Despite these limitations, this study provides a 
valuable addition to the literature on PPIs and HE 
and provides important data arguing for the judi-
cious discontinuance of PPIs in patients with cir-
rhosis. However, we have a difficult time accepting 
PPIs as an independent risk factor for all of the 
deaths observed without knowing more about the 
causes of death and the comorbidities that come 
with PPI use.
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